A Case of Shock Due to nabPTX Administration Successfully Treated with Cytokine Adsorption Therapy
Yoshikawa, K.; Yamamoto, D.; Tsubota, Y.; Sueoka, N.; Chiba, T.; Ishizuka, M.; Kon, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(12): 1358-1360
2017
ISSN/ISBN: 0385-0684 PMID: 29394633 Document Number: 692778
The patient was a 71-year-old woman with ER(+), PgR(-), HER2(3+), and Ki-674 2% breast cancer. After surgery for left breast cancer(Bt+Ax), epirubicin, cyclophosphamide therapy was administered as postoperative adjuvant chemotherapy, and nabPTX plus trastuzumab therapy was started sequentially. The patient was hospitalized due to severe neutrope- nia(neutrophils 0/mm3)from nabPTX, but her condition stabilized after admission. However, the patient suddenly went into shock after 3 days and was thus transferred to the ICU. Her general condition was rapidly improved through cytokine adsorption therapy in the ICU. After 5 days, she was extubated and wheeled back to a general ward. She was discharged without problems in the succeeding months. In this case, FN or cardiovascular diseases was ruled out, and engraftment syndrome was considered given that cytokine adsorption therapy significantly improved the patient's condition. Considering the risk for severe neutropenia in nabPTX administration, clinicians should exercise caution when administering the drug.